Sign in

DSGN on Nasdaq

Design Therapeutics, Inc.

Design Therapeutics, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Carlsbad, California.1 Its shares trade on Nasdaq under the symbol DSGN.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Regen BioPharma Inc, Geron Corporation or Anixa Biosciences Inc, or pick any stock.

  • TickerDSGN on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCarlsbad, California1
  • Incorporated inDE2
  • Business address6005 Hidden Valley Road, Suite 110, Carlsbad, Ca 920112
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-32.8%Return on equity3
-$54.6MFree cash flow3

Financial statements

Revenue453$0 in 2025
0$100.0K$200.0K$300.0K2020: $226.0K$226.0K20202024: $0$020242025: $0$02025
Operating income46753-$79.5M in 2025+854% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$8.3M-$8.3M20202021: -$35.8M-$35.8M2021+330%2022: -$67.6M-$67.6M2022+89%2023: -$78.2M-$78.2M2023+16%2024: -$62.4M-$62.4M2024−20%2025: -$79.5M-$79.5M2025+27%
Net income46753-$69.8M in 2025+743% since 2020
-$80.0M-$60.0M-$40.0M-$20.0M02020: -$8.3M-$8.3M20202021: -$35.5M-$35.5M2021+329%2022: -$63.3M-$63.3M2022+78%2023: -$66.9M-$66.9M2023+6%2024: -$49.6M-$49.6M2024−26%2025: -$69.8M-$69.8M2025+41%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Research and development (including related party amounts of $915 and $891, respectively)$59.1M$44.4M
General and administrative (including related party amounts of $528 and $537, respectively)$20.3M$18.0M
Total operating expenses$79.5M$62.4M
Loss from operations-$79.5M-$62.4M
Interest income$9.7M$12.8M
Net loss-$69.8M-$49.6M
Net loss per share, basic-$1.22-$0.88
Net loss per share, diluted-$1.22-$0.88
Weighted-average shares of common stock outstanding, basic57.3M shares56.6M shares
Weighted-average shares of common stock outstanding, diluted57.3M shares56.6M shares

Compare Design Therapeutics, Inc. with another company

Corporate structure

Design Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Design Therapeutics, Inc.

  • Design Therapeutics, Inc. Carlsbad, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Design Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.2M3 Dec 31, 2025$3.1M3 Dec 31, 2024+5.9%
Accumulated depreciation$2.3M3 Dec 31, 2025$1.7M3 Dec 31, 2024+36.8%
Property and equipment, net$981.0K3 Dec 31, 2025$1.4M3 Dec 31, 2024−30.4%
Operating-lease assets (leased space)$1.4M3 Dec 31, 2025$2.2M3 Dec 31, 2024−35.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$16.9M3 Dec 31, 2025$22.6M3 Dec 31, 2024−25.3%
Marketable securities, current$203.0M3 Dec 31, 2025$222.9M3 Dec 31, 2024−8.9%

Properties, in its own words

We lease approximately 12,370 square feet of laboratory and office space in Carlsbad, California, pursuant to a lease agreement that commenced in September 2021 and expires in December 2029. Additionally, we lease approximately 4,900 square feet of additional office space in the same building, pursuant to a lease amendment that commenced in June 2022 and expires in December 2029. We believe that these facilities will meet our current and near-term needs and that suitable additional space will be available as and when needed.

Item 2 of the 10-K filed Mar 9, 2026.10

Leadership

Who has led Design Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Joao Siffert Md.2021–2023
  2. Pratik Shah2023–now

Chair

  1. Pratik Shah2021–now

President

  1. Joao Siffert Md.2021–2023
  2. Pratik Shah2023–now

Chief operating officer

  1. Sean Jeffries2021–now
2025
Board members and other officers (14)

Timeline

  1. Aug 3, 20268-K Results of operations28
  2. Jun 11, 20268-K Shareholder vote29
  3. May 18, 20268-K Other events30
  4. Apr 28, 20268-K Results of operations; Regulation FD disclosure31
  5. Apr 1, 20268-K Executive or director change32
  6. Mar 9, 20268-K Results of operations33
  7. Jan 30, 20268-K Executive or director change34
  8. Nov 5, 20258-K Results of operations35
  9. Sep 10, 20258-K Executive or director change36
  10. Aug 7, 20258-K Results of operations; Regulation FD disclosure37
  11. Jun 12, 20258-K Shareholder vote38
  12. May 7, 20258-K Results of operations39
  13. Sep 5, 2023New chief executive Pratik Shah becomes CEO11
  14. Mar 25, 2021New chief executive Joao Siffert Md. becomes CEO12

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.30) a share, on Nov 5, 2025.40

When it reported results

  1. Aug 3, 2026Reported quarterly or annual results28
  2. Apr 28, 2026Reported quarterly or annual results31
  3. Mar 9, 2026Reported quarterly or annual results33
  4. Nov 5, 2025Reported quarterly or annual results35
  5. Aug 7, 2025Reported quarterly or annual results37
  6. May 7, 2025Reported quarterly or annual results39
  7. Mar 10, 2025Reported quarterly or annual results41
  8. Nov 7, 2024Reported quarterly or annual results42

Drug trials and FDA: coming up

  1. Dec 2026Phase 1/2 trial readout expected Phase 1/2 trial of DT-216P2 in Friedreich Ataxia: primary completion expected Dec 2026 (ClinicalTrials.gov NCT06874010).43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

197 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 32 major events, 80 insider forms, 30 large holders, 35 other. The latest 20:

  1. Aug 14, 2026SCHEDULE 13G/A EDGAR
  2. Aug 14, 2026SCHEDULE 13G EDGAR
  3. Aug 3, 202610-Q EDGAR
  4. Aug 3, 20268-K EDGAR
  5. Jun 11, 20264 EDGAR
  6. Jun 11, 20264 EDGAR
  7. Jun 11, 20264 EDGAR
  8. Jun 11, 20264 EDGAR
  9. Jun 11, 20264 EDGAR
  10. Jun 11, 20264 EDGAR
  11. Jun 11, 20268-K EDGAR
  12. Jun 9, 2026SCHEDULE 13G EDGAR
  13. May 18, 20268-K EDGAR
  14. May 15, 2026SCHEDULE 13G/A EDGAR
  15. Apr 28, 202610-Q EDGAR
  16. Apr 28, 20268-K EDGAR
  17. Apr 23, 2026DEFA14A EDGAR
  18. Apr 23, 2026DEF 14A EDGAR
  19. Apr 23, 2026ARS EDGAR
  20. Apr 1, 20264 EDGAR

The 197 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 17 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 13, 2025William ArsaniDirectorSale562,627$5.25$3.0MForm 4
Dec 18, 2024Prasad DeepaDirectorSale3,806$6.27$23.9KForm 4
Aug 9, 2024William ArsaniDirectorSale814,874$4.25$3.5MForm 4
Mar 25, 2024Schmid John P.DirectorBuy17,809$3.74$66.6KForm 4
Mar 25, 2024Berger Heather A.DirectorBuy1,300$3.74$4.9KForm 4
Mar 22, 2024Schmid John P.DirectorBuy9,156$3.62$33.1KForm 4
Sep 29, 2023LAPPE RODNEY WDirectorBuy21,000$2.35$49.4KForm 4
Aug 29, 2023Prasad DeepaDirectorBuy12,000$2.31$27.7KForm 4
Aug 29, 2023William ArsaniDirectorBuy1,960,000$2.44$4.8MForm 4
Aug 28, 2023William ArsaniDirectorBuy275,000$2.15$591.2KForm 4
Dec 20, 2022Siffert Joao MDPresident and CEOBuy6,300$8.38$52.8KForm 4
Dec 20, 2022George SimeonDirectorBuy40,000$8.14$325.6KForm 4
Dec 20, 2022SR ONE CAPITAL PARTNERS I, LP10% ownerBuy40,000$8.14$325.6KForm 4
Dec 19, 2022Siffert Joao MDPresident and CEOBuy1,150$8.47$9.7KForm 4
Dec 19, 2022George SimeonDirectorBuy360,000$8.63$3.1MForm 4
Dec 19, 2022SR ONE CAPITAL PARTNERS I, LP10% ownerBuy360,000$8.63$3.1MForm 4
Dec 16, 2022George SimeonDirectorBuy500,000$8.28$4.1MForm 4
Dec 16, 2022SR ONE CAPITAL PARTNERS I, LP10% ownerBuy500,000$8.28$4.1MForm 4
Dec 9, 2022LAPPE RODNEY WDirectorBuy15,000$7.96$119.4KForm 4
Mar 22, 2022Xu StellaDirectorSale1,455$18.63$27.1KForm 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Pratik ShahPh.D.$2.8M$3.5M56
2025Chris M. StorgardM.D.60$1.4M$2.0M56
2025Sean JeffriesPh.D.$1.2M$1.9M56
2024Chief Operating Officer$432.6K$1.3M56
2024PresidentChief Executive Officer and Chairperson$395.0K$789.8K56

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
SR One Capital Management, LP6,526,476$94.4M9.1%No change
Logos Global Management LP3,000,000$43.4M1.9%+1,050,000
Baker Bros. Advisors LP2,678,430$38.8M0.2%+92,452
Driehaus Capital Management LLC2,661,115$38.5M0.2%+916,128
BlackRock, Inc.2,660,024$38.5M0.0%+526,260
Point72 Asset Management, L.P.2,366,453$34.2M0.1%−356,301
Trails Edge Capital Partners, LP2,001,282$29.0M4.6%+1,149,269
Frazier Life Sciences Management, L.P.1,809,854$26.2M0.6%New
Vivo Capital, LLC1,612,903$23.3M2.1%No change
Vanguard Capital Management LLC1,571,022$22.7M0.0%+221,172
Caption Management, LLC1,118,098$16.2M0.6%+1,031,390
Almitas Capital LLC1,026,893$14.9M3.6%−503,442
Geode Capital Management, LLC958,417$13.9M0.0%+265,899
Sofinnova Investments, Inc.865,135$12.5M0.7%New
Fmr LLC776,462$11.2M0.0%−21,949
Morgan Stanley765,425$11.1M0.0%+108,860
State Street Corp736,221$10.7M0.0%+76,646
Woodline Partners LP700,354$10.1M0.0%−261,147
Dimensional Fund Advisors LP694,743$10.1M0.0%+262,903
Goldman Sachs Group Inc656,584$9.5M0.0%+151,866
Jacobs Levy Equity Management, Inc565,597$8.2M0.0%+276,212
Siren, L.L.C.523,212$7.6M0.2%New
Qube Research & Technologies Ltd437,079$6.3M0.0%+402,896
Renaissance Technologies LLC387,913$5.6M0.0%−20,287
Kennedy Capital Management LLC384,036$5.6M0.1%+112,482

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Design Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDesign Therapeutics, Inc.1
  • CIK0001807120
  • Employer ID (EIN)82-392924810
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company10
  • Incorporated inDelaware10
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address6005 Hidden Valley Road, Suite 110, Carlsbad, CA 920111
  • Phone858-293-49001
  • Shares outstanding62,581,651 as of Jul 29, 20269
  • Public float$114.3M as of Jun 30, 202510
  • AuditorErnst & Young LLP, San Diego, California PCAOB ID 42; no auditor attestation of internal control over financial reporting10
  • On EDGAR sinceMar 20, 20201
  • Filings264 in all: 4 (92), 8-K (38), 3 (23), 10-Q (17), SC 13G (9), CORRESP (8), SC 13G/A (8), 144 (6)1
    All 33 form types

    S-8 (6), 10-K (5), DEF 14A (5), DEFA14A (5), SCHEDULE 13G/A (5), ARS (4), UPLOAD (4), EFFECT (3), SCHEDULE 13D/A (3), SCHEDULE 13G (3), D (2), S-3 (2), SC 13D (2), SC 13D/A (2), SEC STAFF LETTER (2), 3/A (1), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), D/A (1), DEFR14A (1), DRS (1), S-1 (1), S-1/A (1)

  • Latest filingsAnnual report (10-K) Mar 9, 2026
    Quarterly report (10-Q) Aug 3, 2026
    Proxy statement (DEF 14A) Apr 23, 2026
    Latest 8-K (8-K) Aug 3, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per shareDSGNThe Nasdaq Global Select Market

From the cover page of the 10-K filed Mar 9, 2026 (Section 12(b) of the Exchange Act).10

Risk factors and legal proceedings

The risks Design Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 9, 2026: 74 risks under these headings, as written.10

  • Risks Related to Our Limited Operating History, Financial Position and Capital Requirements
  • We have a limited operating history, have incurred net losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, may not be able to sustain it.
  • If we are unable to raise additional capital when needed, we may be forced to delay, reduce or eliminate our product development programs or other operations.
  • Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Our financial condition could be adversely affected if the financial institutions in which we hold our cash fail.
  • Risks Related to the Discovery, Development and Regulatory Approval of Our Product Candidates
  • We are early in our development efforts with three product candidates in clinical development and with all of our other research programs currently in the nonclinical or discovery stage. We have a limited history of conducting clinical trials to test our product candidates in humans.
  • Nonclinical and clinical development involves a lengthy and expensive process with uncertain timelines and outcomes, and results of nonclinical studies and clinical trials may not be predictive of future trial results. If development of our programs is unsuccessful or delayed, we may be unable to obtain required regulatory approvals and be unable to commercialize our product candidates on a timely basis, if at all.
  • Our product candidates are based on novel technologies, which make it difficult to predict the timing, results and cost of product candidate development and likelihood of obtaining regulatory approval.
  • If we encounter difficulties or delays enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
  • We are conducting and plan to conduct additional clinical trials for our product candidates outside the United States and the FDA may not accept data from such trials.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
The other 62 risks
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue our clinical trials, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • Early, interim, topline and preliminary data from our nonclinical studies or clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
  • The regulatory approval process is lengthy, expensive and uncertain, and we may be unable to obtain regulatory approval for our product candidates under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of our product candidates and adversely impact our ability to generate revenue, our business and our results of operations.
  • International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects.
  • A health epidemic or pandemic could adversely impact our business and affect our operations, as well as the business or operations of our manufacturers or other third parties with whom we conduct business.
  • We may seek orphan drug designation for our product candidates from the FDA and/or from the European Commission in the future. However, we may be unsuccessful in obtaining or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.
  • A Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval process.
  • Any Breakthrough Therapy designation that we may receive from the FDA, or designations in foreign countries, for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.
  • We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.
  • We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • We may not be successful in our efforts to identify or discover additional product candidates in the future.
  • Risks Related to Manufacturing, Commercialization and Reliance on Third Parties
  • We may rely on third parties to conduct, supervise, and monitor our clinical trials and perform some of our research and nonclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.
  • We contract with third parties for the manufacturing and supply of our product candidates for use in nonclinical testing and clinical trials, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.
  • Changes in methods of product candidate manufacturing may result in additional costs or delays.
  • Any approved products may fail to achieve the degree of market acceptance by physicians, patients, hospitals, healthcare payors and others in the medical community necessary for commercial success.
  • We may not be able to successfully commercialize our product candidates, if approved, due to unfavorable pricing regulations or third-party coverage and reimbursement policies, which could make it difficult for us to sell our product candidates profitably.
  • If the market opportunities for any of our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.
  • Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • If any of our product candidates are approved for marketing and commercialization and we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we will be unable to successfully commercialize our product candidates if and when they are approved.
  • Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.
  • Risks Related to Our In-Licenses and Other Strategic Agreements
  • We may not realize the benefits of any acquisitions, in-license or strategic alliances that we enter into.
  • We may wish to form collaborations in the future with respect to our product candidates, but may not be able to do so or to realize the potential benefits of such transactions, which may cause us to alter or delay our development and commercialization plans.
  • Risks Related to Our Business Operations, Employee Matters and Managing Growth
  • Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
  • We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims.
  • We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
  • We expect to expand our development, regulatory and operational capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • Risks Related to Government Regulation
  • Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, transparency laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may charge for such product candidates.
  • We and the third parties with whom we work are subject to stringent and changing U.S. and foreign laws, regulations and rules, contractual obligations, industry standards, policies and other obligations related to data privacy and security. Our, or our third parties’, actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions, litigation (including class claims) and mass arbitration demands, fines and penalties, disruptions of our business operations, reputational harm and other adverse business impacts.
  • Disruptions to the operations of the FDA, the SEC, other U.S. governmental agencies or comparable foreign regulatory authorities caused by funding shortages, leadership changes, staffing cuts or other staffing shortages, along with uncertainty regarding the potential for new initiatives, laws, regulations, policies and guidance affecting our product candidates or other aspects of our business, could materially and adversely affect our business.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain sufficient intellectual property protection for our platform technologies and product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected.
  • We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
  • Our technology licensed from various third parties may be subject to retained rights.
  • We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
  • We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.
  • If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.
  • We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.
  • Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
  • We may be subject to claims that we have wrongfully hired an employee from a competitor or that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
  • We may rely on trade secrets and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • Risks Related to the Securities Market and Ownership of Our Common Stock
  • An active trading market for our common stock may not be sustained, which may make it difficult for you to sell your shares.
  • The price of our common stock could be subject to volatility related or unrelated to our operations.
  • Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
  • Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
  • We are an “emerging growth company”, and we intend to take advantage of reduced reporting requirements.
  • We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to public company reporting and compliance initiatives.
  • If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
  • Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of operations.
  • Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.
  • We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.
  • We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • Delaware law and provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock.

Legal proceedings

From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors.

The opening of Item 3, Legal Proceedings.10

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56